Relative Risk of Major Risk of Chronic Major Disease Catego ries, by Gender and Gender and verag e Drinkin e Dr g Catego Females Males Disease Disea

Size: px
Start display at page:

Download "Relative Risk of Major Risk of Chronic Major Disease Catego ries, by Gender and Gender and verag e Drinkin e Dr g Catego Females Males Disease Disea"

Transcription

1 38 th IMAG Conference, Amsterdam, October 13-14, 14, 2014 International Meeting on Alcohol and Global Health Overview: All-Cause Mortality Wolfgang Koenig MD, FRCP, FESC, FACC, FAHA Dept. of Internal Medicine II - Cardiology, University of Ulm Medical Center, Ulm, Germany

2 Alcohol Use and Your Health

3 Kiechl et al. Circulation 2014;130: Five-year Changes in Recorded per Capita Alcohol (15+ years) Consumption,

4 Kiechl et al. Circulation 2014;130: Alcohol-attributable Fractions for All-Cause Deaths, 2012

5 Relative Risk of Major Chronic Disease Categories, by Gender and Average Drinking Category Disease ICD-9 code ICD-10 code Malignant neoplasms C00-C97C97 Mouth and oropharynx cancers I 0-20 Females II Drinking Category III 40+ I 0-40 Males II III C00-C14C Esophagus cancer 150 C Liver cancer 155 C Breast cancer Under 45 years of age 174 C years and over Other neoplasms D00-D48D Diabetes mellitus 250 E10-E14E Rehm et al. NIAAA: Understanding the impact of alcohol on human health and well-being, 2003

6 Relative Risk of Major Chronic Disease Categories, by Gender and Average Drinking Category Disease ICD-9 code ICD-10 code Digestive diseases K20-K92K92 I Females II Drinking Category Males III I II Cirrhosis of the liver 571 K70, K III Neuropsychiatric conditions Unipolar major depression , F01-F99, F99, G06-G98G F32-F33F33 RR not available; AF could not be determined otherwise (Rehm et al., in press b) Epilepsy 345 G40-G41G Alcohol use disorders 291, 303, F10 AF 100% AF 100% AF 100% AF 100% AF 100% AF 100% Rehm et al. NIAAA: Understanding the impact of alcohol on human health and well-being, 2003

7 Relative Risk of Major Chronic Disease Categories, by Gender and Average Drinking Category Disease Females Drinking Category Males ICD-9 code ICD-10 code I II III I II III Cardiovascular I00-I99I99 diseases (CVD) Hypertensive disease I10-I13I Coronary heart disease I20-I25I Cerebrovascular disease I60-I69I69 Ischemic stroke Hemorrhagic stroke Other CVD causes , 417, , 424, , 429, , 448, I00, I26- I28, I34- I37, I44- I51, I70- I Rehm et al. NIAAA 2003

8 *Oxid., FMD, Coag., LF and IS, the Heart and Fat Tissue Kiechl et al. Circulation 2014;130: Proposed Mechanistic Insights into Protective* (green) as well as Injurious (red) Effects of Alcohol

9 Di Castelnuovo, A. et al. Arch Intern Med 2006;166: Relative Risk of Total Mortality (95% CI) and Alcohol Intake: Meta-analysis analysis of 34 Prospective Studies Extracted from 56 Curves Using Fixed- and Random-effects Models 6g/d ~1/2 drink 42g/d ~ 4 drinks Max. reduction in women 18% (99%CI 13%-22%) in men 17% (99% CI 15%-19%)

10 Relative Risk of Total Mortality (99% CI) and Alcohol Intake: Meta-analysis analysis of 34 Prospective Studies in - men and women (A) - women (B) - men (C) in the - United States - Europe - other countries (Australia, Japan, and/or China), extracted from adjusted curves Di Castelnuovo, A. et al. Arch Intern Med 2006;166:

11 Ronksley et al. BMJ 2011;342:d671 (84 Studies) WHAT IS ALREADY KNOWN ON THIS TOPIC: Systemic reviews have addressed the association of alcohol consumption with various cardiovascular outcomes However, these reviews are somewhat out of date, and none has comprehensively studied a broad spectrum of relevant cardiovascular end points WHAT THIS STUDY ADDS This meta-analysis analysis provides a summary of current knowledge regarding alcohol associations with six meaningful clinical end points cardiovascular disease mortality, coronary heart disease and mortality, stroke incidence and mortality, and all cause mortality The results confirm the beneficial effects of moderate alcohol consumption and the need to elucidate the underlying pathophysiological mechanisms

12 Ronksley et al. BMJ 2011;342:d671 Forest Plot of Mortality from All Causes Associated with Alcohol Consumption (31 Studies) Lowest Relative Risk of 0.83 ( ) for those consuming g/day

13 Association of Alcohol Consumption With CV or Total Mortality in CVD Patients Study Country No. Sex Follow-up, y Primary Event Secondary Event Doll, UK 5402 Men 13.0 CVD+CV-RF Thun, USA Both 9.0 CVD+CV-RF Janszky, Sweden 1346 Both 8.6 AMI Masunaga, Japan 3845 Men 1.1 AMI Aguilar, USA 2036 Both 3.5 AMI Jackson, USA 1320 Men 4.5 Stroke Mukamal, USA 1913 Both 3.8 AMI Shaper, UK 596 Men 12.8 CHD Valmadrid, USA 262 Both 12.3 ACS Muntwyler, USA 5356 Men 5.0 AMI AC-M, CV-M AC-M, CV-M AC-M,CV-M, CV-M+CVD AC-M, CV-M+CVD AC-M, CV-M, CV-M+CVD AC-M, CV-M AC-M, CV-M AC-M, CV-M CV-M AC-M, CV-M UK indicates United Kingdom; CV-RF, cardiovascular risk factors; AC-M, all-cause mortality; CV-M, cardiovascular mortality; USA, United States of America; and ACS, acute coronary syndrome. Funded by ERAB Costanzo et al. Circulation 2010;121:

14 Relative Risk of Cardiovascular Mortality Relative Risks of Cardiovascular Mortality with 1.4 Different Intakes of Alcohol in CVD Patients Funded by ERAB Alcohol Consumption (grams/day) Janszky, 2008 Aguilar, 2006 Jackson, 2003 Mukamal, 2001 Shaper, 2000 Valmadrid, 1999 Muntwyler, 1998 Costanzo et al. Circulation 2010;121:

15 Relative Risk of All-Cause Mortality Relative Risks of Total Mortality with Different 1.4 Intakes of Alcohol in Studies of CVD Patients Funded by ERAB Alcohol Consumption (grams/day) Janszky, 2008 Masunaga, 2006 (age <65yr) Masunaga, 2006 (age 65yr) Aguilar, 2006 Jackson, 2003 Mukamal, 2001 Shaper, 2000 Muntwyler, 1998 (age <65yr) Muntwyler, 1998 (age 65yr) Costanzo et al. Circulation 2010;121:

16

17 Mukamal et al. JAMA 2001;285: Survival Following Acute Myocardial Infarction (AMI) According to Average Alcohol Consumption

18 Mukamal et al. JAMA 2001;285: Hazard Ratios for Mortality Following Acute Myocardial Infarction According to Alcohol Consumption

19 Mukamal et al. JAMA 2001;285: Hazard Ratios for All-Cause Mortality According to Alcohol Consumption by Predominant Beverage Type*

20 Pai et al. Eur Heart J 2012;33:

21 Pai et al. Eur Heart J 2012;33: Baseline Lifestyle and Clinical Characteristics of 1818 Men with Incident Non-Fatal MI in the HPFU Study

22 Pai et al. Eur Heart J 2012;33: Long-term Alcohol Intake and Risks for Total Death and CVD Death Among 1818 Men with Incident Non-Fatal MI

23 Pai et al. Eur Heart J 2012;33: Beverage-specific Long-term Alcohol Consumption and Risks of Total Death Among 1818 Men with Incident Non-Fatal MI

24 Zaridze et al. Lancet 2014;383: All-Cause Mortality, Males Aged Years, in Russia From and in the UK From

25 Alcohol and Cardiovascular Mortality Common Sense and Scientific Truth*...The risks of moderate drinking differ by sex, age, personal history, and family history. As is often the case in medical practice, advice about life-style must be based on something less than certainty. There is no substitute for balanced judgement by a knowledgeable, objective health professional. What is required is a synthesis of common sense and the best available scientific facts. *Editorial by A.L. Klatsky JACC 2010;55:

26 Department of Cardiology University of Ulm Medical Center The New York Times, Sunday May 8, 2005 University of Ulm Medical Center

27 Alcohol Consumption in Relation to MI Diagnosis Pai et al. Eur Heart J 2012;33:

28

29 Kaplan-Meier Estimates of Survival After Acute MI Among Binge Drinkers and Nonbinge Drinkers* *matched by Propensity Score Mukamal et al. Circulation 2005;112:

30 Mukamal et al. Circulation 2005;112: Adjusted HRs for Mortality After Acute MI According to Binge Drinking and Usual Alcohol Intake

31 Mukamal et al. Circulation 2005;112: HRs and 95% CIs for All-Cause, Cardiovascular, and Noncardiovascular Mortality After Acute MI According to Drinking Among Onset Study Participants

32 Mukamal et al. Circulation 2005;112: Additional Adjusted Analyses of Binge Drinking and Total Mortality Among Onset Study Participants

33 Pai et al. Eur Heart J 2012;33: Change in Alcohol Consumption Pattern and Risks for Total Death and Death due to CVD Among the 1633 Men who Reported Alcohol Consumption on the Questionnaires Immediately Before and After MI Diagnosis

BEER AND CARDIOVASCULAR HEALTH: EFFECTS ON MORBIDITY AND MORTALITY. Simona Costanzo THE 7 TH EUROPEAN BEER AND HEALTH SYMPOSIUM

BEER AND CARDIOVASCULAR HEALTH: EFFECTS ON MORBIDITY AND MORTALITY. Simona Costanzo THE 7 TH EUROPEAN BEER AND HEALTH SYMPOSIUM BEER AND CARDIOVASCULAR HEALTH: EFFECTS ON MORBIDITY AND MORTALITY Simona Costanzo Department of Epidemiology and Prevention IRCCS Mediterranean Neurological Institute Pozzilli (IS), Italy simona.costanzo@neuromed.it

More information

The burden caused by alcohol

The burden caused by alcohol The burden caused by alcohol Presentation at REDUCING THE HARM CAUSED BY ALCOHOL: A COORDINATED EUROPEAN RESPONSE Tuesday, November 13 Jürgen Rehm Centre for Addiction and Mental Health, Toronto, Canada

More information

Jürgen Rehm 1,2,3, Robert Mann 1,2 & Jayadeep Patra 1 1 Centre for Addiction and Mental Health, Toronto, Canada 2 Dalla Lana School of Public Health,

Jürgen Rehm 1,2,3, Robert Mann 1,2 & Jayadeep Patra 1 1 Centre for Addiction and Mental Health, Toronto, Canada 2 Dalla Lana School of Public Health, Jürgen Rehm,2,3, Robert Mann,2 & Jayadeep Patra Centre for Addiction and Mental Health, Toronto, Canada 2 Dalla Lana School of Public Health, University of Toronto, Canada 3 TU Dresden, Germany Based on

More information

Dyslipidemia in women: Who should be treated and how?

Dyslipidemia in women: Who should be treated and how? Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European

More information

Alcohol Consumption and Mortality Risks in the U.S. Brian Rostron, Ph.D. Savet Hong, MPH

Alcohol Consumption and Mortality Risks in the U.S. Brian Rostron, Ph.D. Savet Hong, MPH Alcohol Consumption and Mortality Risks in the U.S. Brian Rostron, Ph.D. Savet Hong, MPH 1 ABSTRACT This study presents relative mortality risks by alcohol consumption level for the U.S. population, using

More information

I t is established that regular light to moderate drinking is

I t is established that regular light to moderate drinking is 32 CARDIOVASCULAR MEDICINE Taking up regular drinking in middle age: effect on major coronary heart disease events and mortality S G Wannamethee, A G Shaper... See end of article for authors affiliations...

More information

The Clinical Unmet need in the patient with Diabetes and ACS

The Clinical Unmet need in the patient with Diabetes and ACS The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge

More information

A nationwide population-based study. Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD

A nationwide population-based study. Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD The Association of Clinical Symptomatic Hypoglycemia with Cardiovascular Events and Total Death in Type 2 Diabetes Mellitus A nationwide population-based study Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD Taipei

More information

Alcohol and Cancer: Defining the Exposure and Key Milestones in Establishing the Relationship

Alcohol and Cancer: Defining the Exposure and Key Milestones in Establishing the Relationship Alcohol and Cancer: Defining the Exposure and Key Milestones in Establishing the Relationship Susan M. Gapstur, PhD, MPH Vice President, Epidemiology American Cancer Society 1 Disclosure Information SUSAN

More information

Supplement materials:

Supplement materials: Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction

More information

The Mediterranean Diet: The Optimal Diet for Cardiovascular Health

The Mediterranean Diet: The Optimal Diet for Cardiovascular Health The Mediterranean Diet: The Optimal Diet for Cardiovascular Health Vasanti Malik, ScD Research Scientist Department of Nutrition Harvard School of Public Health Cardiovascular Disease Prevention International

More information

Overview. The Mediterranean Diet: The Optimal Diet for Cardiovascular Health. No conflicts of interest or disclosures

Overview. The Mediterranean Diet: The Optimal Diet for Cardiovascular Health. No conflicts of interest or disclosures The Mediterranean Diet: The Optimal Diet for Cardiovascular Health No conflicts of interest or disclosures Vasanti Malik, ScD Research Scientist Department of Nutrition Harvard School of Public Health

More information

The burden of death, disease and disability due to alcohol in New Zealand

The burden of death, disease and disability due to alcohol in New Zealand The burden of death, disease and disability due to alcohol in New Zealand Research summary September 2004 Jennie Connor, Joanna Broad, Rod Jackson School of Population Health, University of Auckland Stephen

More information

Diabetes Mellitus: A Cardiovascular Disease

Diabetes Mellitus: A Cardiovascular Disease Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular

More information

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial Michelle L. O Donoghue, Robert P. Giugliano, Anthony C. Keech, Estella Kanevsky, KyungAh Im, Peter S. Sever, Terje

More information

Fasting or non fasting?

Fasting or non fasting? Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues

More information

Barnyard Brouhaha: What About Dairy and Eggs in the Diet? Edwin Cox, M.D. OLLI

Barnyard Brouhaha: What About Dairy and Eggs in the Diet? Edwin Cox, M.D. OLLI Barnyard Brouhaha: What About Dairy and Eggs in the Diet? Edwin Cox, M.D. OLLI Dairy and Eggs Good sources of protein Good sources of vitamin B12 Associated with controversy: risk regarding ASCVD risk

More information

Overview of effects of alcohol intake on cardiovascular disease

Overview of effects of alcohol intake on cardiovascular disease Beverage specific effects Overview of effects of alcohol intake on cardiovascular disease Dr. Ramon Estruch Department of Internal Medicine, Barcelona University, Spain. CIBER OBN Institute of Health Carlos

More information

The TNT Trial Is It Time to Shift Our Goals in Clinical

The TNT Trial Is It Time to Shift Our Goals in Clinical The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia

More information

ORIGINAL INVESTIGATION. Alcohol Consumption and Mortality in Men With Preexisting Cerebrovascular Disease

ORIGINAL INVESTIGATION. Alcohol Consumption and Mortality in Men With Preexisting Cerebrovascular Disease ORIGINAL INVESTIGATION Alcohol Consumption and Mortality in Men With Preexisting Cerebrovascular Disease Vicki A. Jackson, MD; Howard D. Sesso, ScD; Julie E. Buring, ScD; J. Michael Gaziano, MD Background:

More information

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention

More information

Wine Drinking and Risks of Cardiovascular Complications After Recent Acute Myocardial Infarction

Wine Drinking and Risks of Cardiovascular Complications After Recent Acute Myocardial Infarction Wine Drinking and Risks of Cardiovascular Complications After Recent Acute Myocardial Infarction Michel de Lorgeril, MD; Patricia Salen, BSc; Jean-Louis Martin, PhD; François Boucher, PhD; François Paillard,

More information

Melanie Nichols, 1,2 Peter Scarborough, 2 Steven Allender, 1,2 Mike Rayner 2

Melanie Nichols, 1,2 Peter Scarborough, 2 Steven Allender, 1,2 Mike Rayner 2 Open Access Research What is the optimal level of population alcohol consumption for chronic disease prevention in England? Modelling the impact of changes in average consumption levels Melanie Nichols,

More information

Examining the relationship between beverage intake and cardiovascular health. Ian Macdonald University of Nottingham UK

Examining the relationship between beverage intake and cardiovascular health. Ian Macdonald University of Nottingham UK Examining the relationship between beverage intake and cardiovascular health Ian Macdonald University of Nottingham UK Outline Assessment of evidence in relation to health risks of dietary components Cardiovascular

More information

Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease

Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease D. Dallmeier 1, D. Rothenbacher 2, W. Koenig 1, H. Brenner

More information

Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence

Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Karen E. Aspry, M.D., M.S., ABCL, FACC Assistant Professor of Medicine (Clinical) Alpert Medical School of Brown University

More information

Is Lower Better for LDL or is there a Sweet Spot

Is Lower Better for LDL or is there a Sweet Spot Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,

More information

CVD risk assessment using risk scores in primary and secondary prevention

CVD risk assessment using risk scores in primary and secondary prevention CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities

More information

Preventive Cardiology Scientific evidence

Preventive Cardiology Scientific evidence Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention

More information

Alcohol and cancer. Peter Anderson MD, MPH, PhD

Alcohol and cancer. Peter Anderson MD, MPH, PhD Alcohol and cancer Peter Anderson MD, MPH, PhD Professor, Substance Use, Policy and Practice, Institute of Health and Society, Newcastle University, England Professor, Alcohol and Health, Faculty of Health,

More information

Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI

Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI Dr Sasha Koul, MD Dept of Cardiology, Lund University Hospital, Lund, Sweden

More information

Glycemic control a matter of life and death

Glycemic control a matter of life and death Glycemic control a matter of life and death Linda Garcia Mellbin MD PhD Specialist in Cardiology & Internal medicine Dep of Cardiology Karolinska University Hospital /Karolinska Institutet Mortality (%)

More information

Misperceptions still exist that cardiovascular disease is not a real problem for women.

Misperceptions still exist that cardiovascular disease is not a real problem for women. Management of Cardiovascular Risk Factors in the Cynthia A., MD University of California, San Diego ARHP 9/19/08 Disclosures Research support Wyeth, Lilly, Organon, Novo Nordisk, Pfizer Consultant fees

More information

Name of Policy: Measurement of Long-Chain Omega-3 Fatty Acids in Red Blood Cell Membranes as a Cardiac Risk Factor

Name of Policy: Measurement of Long-Chain Omega-3 Fatty Acids in Red Blood Cell Membranes as a Cardiac Risk Factor Name of Policy: Measurement of Long-Chain Omega-3 Fatty Acids in Red Blood Cell Membranes as a Cardiac Risk Factor Policy #: 239 Latest Review Date: July 2010 Category: Laboratory Policy Grade: Active

More information

Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension

Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine

More information

Managing HTN in the Elderly: How Low to Go

Managing HTN in the Elderly: How Low to Go Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular

More information

Antihypertensive Trial Design ALLHAT

Antihypertensive Trial Design ALLHAT 1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes

More information

Controversies in Preventative Cardiology

Controversies in Preventative Cardiology Controversies in Preventative Cardiology Francisco Lopez-Jimenez, M.D., M.Sc, FACC, FAHA Professor of Medicine, Mayo Medical School Chair, Division of Preventive Cardiology Co-Director, Artificial Intelligence

More information

J. Michael Gaziano, M.D., M.P.H. European Society of Cardiology August 26 th 2018

J. Michael Gaziano, M.D., M.P.H. European Society of Cardiology August 26 th 2018 ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events): A Study to Assess the Efficacy and Safety of Aspirin in Patients at Moderate Risk of Cardiovascular Disease J. Michael Gaziano, M.D., M.P.H.

More information

Nutraceuticals and Cardiovascular Disease: Are we fishing?

Nutraceuticals and Cardiovascular Disease: Are we fishing? Nutraceuticals and Cardiovascular Disease: Are we fishing? ACC Rockies 2013 March 20,2013 Sheri L. Koshman BScPharm, PharmD, ACPR Assistant Professor, Division of Cardiology, University of Alberta sheri.koshman@ualberta.ca

More information

New Antihypertensive Strategies to Improve Blood Pressure Control

New Antihypertensive Strategies to Improve Blood Pressure Control New Antihypertensive Strategies to Improve Blood Pressure Control Antonio Coca, MD, PhD,, FRCP, FESC Hypertension and Vascular Risk Unit Department of Internal Medicine. Hospital Clínic (IDIBAPS) University

More information

Modifiable Up-Stream Risk Factors:

Modifiable Up-Stream Risk Factors: Modifiable Up-Stream Risk Factors: Recent Studies in AF Prevention Behzad Pavri, MD, FACC, FHRS Professor of Medicine Director, CCEP Fellowship Thomas Jefferson University Hospital, Philadelphia, USA Disclosures

More information

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National

More information

Methods. OR and PAR both presented with 99% confidence intervals. All analyses adjusted for age, sex and region.

Methods. OR and PAR both presented with 99% confidence intervals. All analyses adjusted for age, sex and region. INTERHEART: Aims 1. To evaluate the association (odds ratio) of risk factors for MI globally, and in each region; and among major ethnic groups in the world. 2. To quantify the impact of each risk factor

More information

Table Cohort studies of consumption of alcoholic beverages and cancers of the lymphatic and haematopoietic system in the general population

Table Cohort studies of consumption of alcoholic beverages and cancers of the lymphatic and haematopoietic system in the general population categories Lim et al., (2007), USA, The National Institutes of Health-former American Association of Retired Persons (NIH- AARP) Diet and Health Study 473984 participants with correct questionnaire and

More information

Timing of angiography for high- risk ACS

Timing of angiography for high- risk ACS Timing of angiography for high- risk ACS Christian Spaulding, MD, PhD, FESC, FACC Cardiology Department Cochin Hospital, Inserm U 970 Paris Descartes University Paris, France A very old story. The Interventional

More information

7 th Munich Vascular Conference

7 th Munich Vascular Conference 7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.

More information

I t is well established that non-insulin dependent diabetes is

I t is well established that non-insulin dependent diabetes is 1398 CARDIOVASCULAR MEDICINE Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease S G Wannamethee, A G Shaper, L Lennon... See end of article

More information

Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute

Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated

More information

Blood Pressure Treatment Goals

Blood Pressure Treatment Goals Blood Pressure Treatment Goals Kenneth Izuora, MD, MBA, FACE Associate Professor UNLV School of Medicine November 18, 2017 Learning Objectives Discuss the recent studies on treating hypertension Review

More information

Blood Pressure Targets: Where are We Now?

Blood Pressure Targets: Where are We Now? Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy

More information

Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD

Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD Sao Paulo Medical School Sao Paolo, Brazil Subclinical atherosclerosis in CVD risk: Stratification & management Prof.

More information

High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients with Stable Coronary Heart Disease: KAROLA Study 8 Year FU

High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients with Stable Coronary Heart Disease: KAROLA Study 8 Year FU ESC Congress 2011 Paris, France, August 27-31 KAROLA Session: Prevention: Are biomarkers worth their money? Abstract # 84698 High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients

More information

Alcohol (Minimum Pricing) (Scotland) Bill. Chest Heart & Stroke Scotland

Alcohol (Minimum Pricing) (Scotland) Bill. Chest Heart & Stroke Scotland Alcohol (Minimum Pricing) (Scotland) Bill Chest Heart & Stroke Scotland Chest Heart & Stroke Scotland (CHSS) aims to improve the quality of life for people in Scotland affected by chest, heart and stroke

More information

Figure 1 Modelling of diseases in PRIMEtime (after Barendregt et al. [7])

Figure 1 Modelling of diseases in PRIMEtime (after Barendregt et al. [7]) PRIMEtime PRIMEtime is a new model that combines elements of the PRIME model [1], which estimates the effect of population-level changes in diet, physical activity, and alcohol and tobacco consumption

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix Increased Risk of Atrial Fibrillation and Thromboembolism in Patients with Severe Psoriasis: a Nationwide Population-based Study Tae-Min Rhee, MD 1, Ji Hyun Lee, MD 2, Eue-Keun Choi,

More information

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of

More information

STATIN THERAPY IN THE ELDERLY: THERE ARE MILES TO GO BEFORE WE SLEEP

STATIN THERAPY IN THE ELDERLY: THERE ARE MILES TO GO BEFORE WE SLEEP STATIN THERAPY IN THE ELDERLY: THERE ARE MILES TO GO BEFORE WE SLEEP Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA, FCCP, FAHA, FACC Director of Preventative Cardiology CGH Medical Center, Sterling, Illinois

More information

Clinical and Economic Value of Rivaroxaban in Coronary Artery Disease

Clinical and Economic Value of Rivaroxaban in Coronary Artery Disease CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban

More information

The earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College

The earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College The earlier BP control the better cardiovascular outcome Jin Oh Na Cardiovascular center Korea University Medical College Index Introduction HOPE-3 Trial Sprint Study Summary Each 2 mmhg decrease in SBP

More information

Role of alcohol in the Eastern European mortality crisis

Role of alcohol in the Eastern European mortality crisis Role of alcohol in the Eastern European mortality crisis Martin Bobak Department of Epidemiology and Public Health Multiple influences on health Social structure Corruption Exclusion Mass privatisation

More information

T. Suithichaiyakul Cardiomed Chula

T. Suithichaiyakul Cardiomed Chula T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial

More information

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t? Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial

More information

Blood Pressure Targets in Diabetes

Blood Pressure Targets in Diabetes Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet

More information

New York Cardiovascular Symposium New York, December New York Hilton Midtown

New York Cardiovascular Symposium New York, December New York Hilton Midtown New York Cardiovascular Symposium New York, December 11-13 2015 New York Hilton Midtown Session IV: Trends and Challenges of Prevention December 11 2015 15:15-17:30 Aspirin Therapy in Primary Cardiovascular

More information

Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.

Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν. Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,

More information

Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center

Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes

More information

The University of Mississippi School of Pharmacy

The University of Mississippi School of Pharmacy LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.

More information

American Academy of Insurance Medicine

American Academy of Insurance Medicine American Academy of Insurance Medicine October 2012 Dr. Alison Moy Liberty Mutual Dr. John Kirkpatrick Thrivent Financial for Lutherans 1 59 year old male, diagnosed with T2DM six months ago Nonsmoker

More information

Rikshospitalet, University of Oslo

Rikshospitalet, University of Oslo Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular

More information

Macrovascular Disease in Diabetes

Macrovascular Disease in Diabetes Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based

More information

HORMONE REPLACEMENT THERAPY

HORMONE REPLACEMENT THERAPY TRIALS OF HR RUTH (Barrett- Connor et al 29 ) JULY 2006 (Country) mean ± sd, range International trial 67.5 an Placebo component in 67.5 ± 6.7 women with Raloxifene or multiple 67.5 ± 6.6 risk factors

More information

Alcohol and the heart: to abstain or not to abstain?

Alcohol and the heart: to abstain or not to abstain? Thomas Jefferson University Jefferson Digital Commons Cardiology Faculty Papers Department of Cardiology 4-15-2013 Alcohol and the heart: to abstain or not to abstain? Rajesh Movva, MD, MRCP Albert Einstein

More information

Supplementary webappendix

Supplementary webappendix Supplementary webappendix This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Ray K K, Seshasai S R K, Wijesuriya S,

More information

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of

More information

Heart Disease Genesis

Heart Disease Genesis Heart Disease Genesis The Ultimate Lecture on CAD origins Petr Polasek MD FRCPC FACC Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,

More information

Sugar consumption and health: an update of the evidence

Sugar consumption and health: an update of the evidence Sugar consumption and health: an update of the evidence Dr Charlotte Evans c.e.l.evans@leeds.ac.uk Lecturer in nutritional epidemiology School of Food Science and Nutrition, University of Leeds FDIN 8

More information

NUTRITION IN THE AGE OF EVIDENCE D A N A H. M A N N I N G P H A R M. D., R. D., L D N

NUTRITION IN THE AGE OF EVIDENCE D A N A H. M A N N I N G P H A R M. D., R. D., L D N NUTRITION IN THE AGE OF EVIDENCE D A N A H. M A N N I N G P H A R M. D., R. D., L D N OBJECTIVES List controversial points from the current Dietary Guidelines for Americans (DGA). Recognize the policy

More information

Folate, vitamin B 6, and vitamin B 12 are cofactors in

Folate, vitamin B 6, and vitamin B 12 are cofactors in Research Letters Dietary Folate and Vitamin B 6 and B 12 Intake in Relation to Mortality From Cardiovascular Diseases Japan Collaborative Cohort Study Renzhe Cui, MD; Hiroyasu Iso, MD; Chigusa Date, MD;

More information

Welcome! Mark May 14, Sat!

Welcome! Mark May 14, Sat! Welcome! Mark May 14, Sat! Do We Have All Answers with Statins In Treating Patients with Hyperlipidemia? Kwang Kon Koh, MD, PhD, FACC, FAHA Cardiology, Gil Heart Center, Gachon Medical School, Incheon,

More information

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline

More information

Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study

Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Conflict of interest disclosure None Committee of Scientific Affairs Committee

More information

Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center

Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode

More information

Weigh the benefit of statin treatment: LDL & Beyond

Weigh the benefit of statin treatment: LDL & Beyond Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research

More information

GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS

GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental

More information

Dabigatran Evidence in Real Practice

Dabigatran Evidence in Real Practice ADVANCES IN CARDIAC ARRHYTHMIAS and GREAT INNOVATIONS IN CARDIOLOGY XXVII GIORNATE CARDIOLOGICHE TORINESI Torino, Centro Congressi Unione Industriale 23-24 Ottobre 2015 Dabigatran Evidence in Real Practice

More information

Heart Disease and Stroke Statistics 2010 Update. 2009, American Heart Association. All rights reserved.

Heart Disease and Stroke Statistics 2010 Update. 2009, American Heart Association. All rights reserved. Heart Disease and Stroke Statistics 21 Update Questions on statistics? mailto:nancy.haase@heart.org Audio-visual questions? mailto:david.brentz@heart.org Please keep the red wave and logo attached to these

More information

Mortality in relation to alcohol consumption: a prospective study among male British doctors

Mortality in relation to alcohol consumption: a prospective study among male British doctors IJE vol.34 no.1 International Epidemiological Association 2005; all rights reserved. International Journal of Epidemiology 2005;34:199 204 Advance Access publication 12 January 2005 doi:10.1093/ije/dyh369

More information

The relationships between alcohol, wine and cardiovascular diseases Areview

The relationships between alcohol, wine and cardiovascular diseases Areview Nutrition and Aging 3 (2015) 55 88 DOI 10.3233/NUA-150052 IOS Press The relationships between alcohol, wine and cardiovascular diseases Areview 55 Creina S. Stockley The Australian Wine Research Institute,

More information

Barnyard Brouhaha: What About Dairy and Eggs in the Diet? Edwin Cox, M.D. OLLI

Barnyard Brouhaha: What About Dairy and Eggs in the Diet? Edwin Cox, M.D. OLLI Barnyard Brouhaha: What About Dairy and Eggs in the Diet? Edwin Cox, M.D. OLLI Dairy and Eggs Good sources of protein Good sources of vitamin B12 Associated with controversy: risk regarding ASCVD risk

More information

Complications of Diabetes: Screening and Prevention

Complications of Diabetes: Screening and Prevention Complications of Diabetes: Screening and Prevention Dr Steve Cleland Consultant Physician GGH and QEUH Diabetes Staff Education Course June 17 Diabetic Complications Microvascular: Retinopathy Nephropathy

More information

Can foods change your health? Good fats and bad fats: what is the evidence? Kay-Tee Khaw. Main categories of fats

Can foods change your health? Good fats and bad fats: what is the evidence? Kay-Tee Khaw. Main categories of fats Can foods change your health? Good fats and bad fats: what is the evidence? Kay-Tee Khaw UNIVERSITY OF CAMBRIDGE Hong Kong July 6 213 Yerushalmy J Hilleboe HE NY State J Med 1957 Coronary heart disease

More information

Decline in CV-Mortality

Decline in CV-Mortality Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer

More information

Antithrombotic therapy in the ACS patient with atrial fibrillation

Antithrombotic therapy in the ACS patient with atrial fibrillation Antithrombotic therapy in the ACS patient with atrial fibrillation Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Great Minds,

More information

Effects of alcohol consumption on mortality in patients with Type 2 diabetes mellitus

Effects of alcohol consumption on mortality in patients with Type 2 diabetes mellitus Diabetologia (2003) 46:1581 1585 DOI 10.1007/s00125-003-1209-2 Effects of alcohol consumption on mortality in patients with Type 2 diabetes mellitus P. Diem, M. Deplazes, R. Fajfr, A. Bearth, B. Müller,

More information

Key causes of preventable deaths in New Zealand In a population of 10,000 New Zealanders, every year there will be about:

Key causes of preventable deaths in New Zealand In a population of 10,000 New Zealanders, every year there will be about: Preventive care - Chronic Disease Management in primary care: a population perspective Rod Jackson University of Auckland New Zealand (22/11/8) Key causes of preventable deaths in New Zealand In a population

More information

CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study. Results at 1 Year

CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study. Results at 1 Year CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study Results at 1 Year André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University

More information

Is there a mechanism of interaction between hypertension and dyslipidaemia?

Is there a mechanism of interaction between hypertension and dyslipidaemia? Is there a mechanism of interaction between hypertension and dyslipidaemia? Neil R Poulter International Centre for Circulatory Health NHLI, Imperial College London Daegu, Korea April 2005 Observational

More information

Lipid Management 2013 Statin Benefit Groups

Lipid Management 2013 Statin Benefit Groups Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date

More information

Coronary Heart Disease in Women Go Red for Women

Coronary Heart Disease in Women Go Red for Women Coronary Heart Disease in Women Go Red for Women Dr Fiona Stewart Green Lane Cardiovascular Service and National Women s Health Auckland City Hospital Auckland Heart Group Women are Different from Men

More information